Project Details
Description
A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk,Non-Muscle Invasive Bladder Cancer
Status | Finished |
---|---|
Effective start/end date | 7/5/18 → 7/30/23 |
Funding
- BRISTOL-MYERS SQUIBB COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.